The US market size for this BRAND is $1.3 billion (Rs8,840cr) as per the latest IMS data.
This ANDA will be manufactured at another USFDA approved contract manufacturing facility (CMO) for 2 years, the company said in the filing.
The company already filed a complex ANDA in September 2017, targeting Cardiology segment with a market size of $200 million (Rs1,360cr) as per latest IMS data.
This product has a limited competition in the market, and hence, the company is expecting good revenues and profits from this product, it added.
The stock is currently trading at Rs36.90 up by Rs3.35 or 9.99% from its previous closing of Rs33.55 on the BSE.
The scrip opened at Rs33.40 and has touched a high and low of Rs36.90 and Rs33 respectively.